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Clear cut-off levels could aid clinicians in identifying patients with a risk of fatal outcomes or
complications such as deep infection foci in Staphylococcus aureus bacteremia (SAB). Cut-
off levels for widely used clinical follow-up parameters including serum C-reactive protein
(CRP) levels and white blood cell counts (WBC) have not been previously studied.
Methods
430 adult SAB patients in Finland took part in prospective multicentre study in which their
CRP levels and WBC counts were measured on the day of the positive blood culture, every
other day during the first week, twice a week during hospitalization and at 30 days. Receiver
operating characteristic (ROC) analysis was used to evaluate the prognostic value of CRP
andWBC on the day of the positive blood culture and at days 4, 7, and 14 in predicting mor-
tality and the presence of deep infections at 30 days. Adjusted hazard ratios (HR) for CRP
level andWBC count cut-off values for mortality were calculated by the Cox regression anal-
ysis and adjusted odds ratios (OR) for cut-off values to predict the presence of deep infec-
tion by the binary logistic regression analysis.
Results
The succumbing patients could be distinguished from the survivors, starting on day 4 after
the positive blood culture, by higher CRP levels. Cut-off values of CRP for day 30 mortality
in adjusted analysis, that significantly predicted fatal outcome were at day 4 CRP >103 mg/
L with sensitivity of 77%, specificity of 55%, and HR of 3.5 (95% CI, 1.2–10.3; p = 0.024), at
day 14 CRP >61 mg/L with a sensitivity of 82%, specificity of 80% and HR of 3.6 (95% CI,
1.1–10.3; p<0.039) and cut-off value of WBC at day 14 >8.6 x109/L was prognostic with sen-
sitivity of 77%, specificity of 78% and HR of 8.2 (95% CI, 2.9–23.1; p<0.0001). Cut-off
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values for deep infection in adjusted analysis were on the day of the positive blood culture
CRP >108 mg/L with sensitivity of 77%, specificity of 60%, and HR of 2.6 (95% CI, 1.3–4.9;
p = 0.005) and at day 14 CRP >22 mg/L with sensitivity of 59%, specificity of 68%, and HR
of 3.9 (95% CI, 1.6–9.5; p = 0.003). The lack of decline of CRP in 14 days or during the sec-
ond week were neither prognostic nor markers of deep infection focus.
Conclusions
CRP levels have potential for the early identification of SAB patients with a greater risk for
death and deep infections.
Introduction
Staphylococcus aureus is one of the most frequent isolates identified in bloodstream infections.
Bacteremia due to S. aureus (SAB) carries high mortality [1,2], and complications such as deep
infection foci are found in 60–80% of patients [3–5]. The prognosis in SAB prognosis is mainly
determined by the severity of the underlying diseases, immunosuppressive treatment, severity
of sepsis and development of deep infections, such as pneumonia [3,6–9]. Prognostic markers
could enable the early identification of patients with complications and guide treatment deci-
sions, thereby possibly improving the prognosis.
Numerous biomarkers have been evaluated for potential clinical use, but their use in prac-
tice has been scarce [10]. We reported that a new soluble urokinase plasminogen activator
receptor (suPAR) could be used to find SAB patients at risk of fatal outcome but could not
identify patients with complications such as deep infections [11]. The apoptosis marker cell
free-DNA in plasma was recently shown to be associated with a high sequential organ failure
assessment (SOFA) score in bacteremic patients [12] and could identify patients with a risk of
fatal outcome in intensive care units (ICU) but not in general wards [13]. Procalcitonin (PCT)
has been shown to have potential for identifying SAB patients with endocarditis [14,15]. How-
ever, no biomarkers that would be helpful in finding other deep infections in SAB patients have
been described.
C-reactive protein (CRP) is an acute-phase protein that is widely used in clinical settings. It
is rapidly synthesized in hepatocytes following infection, injury or trauma [16]. Increasing
CRP concentrations have been shown to be useful for the detection of sepsis or organ dysfunc-
tion [16], whereas a rapid decrease in CRP level has been reported to be one of the earliest
markers of improvement [17]. CRP has been recognized as a good marker of systemic inflam-
mation and a valuable clinical tool in severe infections [18], but clear cut-off levels to guide
clinical decisions in SAB have not been demonstrated. The maximal CRP level might not be
useful because it is influenced by genetic variation in the genes responsible for CRP synthesis
[19]. This study was undertaken to assess CRP concentrations at various time points during
SAB infection that would enable to identify patients with complications. We prospectively fol-
lowed 430 patients with SAB to evaluate the correlation of CRP levels and for comparison
WBC counts on the day of the positive blood culture and at days 4, 7 and 14 thereafter with
30-day mortality and the presence of deep infections.
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Patients and Methods
Patient population
Four hundred and thirty patients with a blood culture positive for S. aureus were recruited con-
secutively from five university hospitals and seven tertiary care hospitals in Finland between
1999 and 2002. [20,21]. The median time between blood culture sampling and study inclusion
was 3 days. The trial primarily aimed to examine the potential of two fluoroquinolones (trova-
floxacin or levofloxacin) to reduce the high mortality and complications associated with SAB
when added to the standard treatment and then patients were randomly assigned to receive
standard antibiotic therapy or that together with a fluoroquinolone. Thereafter, all patients
were prospectively followed for 3 months and the study treatments were open. Parenteral clox-
acillin or dicloxacillin were used as the standard antibiotic therapy in 327 out of 430 (76%)
patients. All other antimicrobials were provided less frequently administered [cefuroxime in 80
(19%) patients and vancomycin in 8 (2%) patients]. Rifampicin was added only in cases of
deep infection and was given to 306 (71%) patients.
The exclusion criteria were bacteremia due to methicillin-resistant S. aureus (MRSA)
(n = 5), age younger than 18 years, proven or suspected pregnancy, breastfeeding, epilepsy,
another bacteremia during the previous 28 days, polymicrobial bacteremia ( 3 microbes), his-
tory of allergy to any quinolone antibiotic, previous tendinitis during fluoroquinolone therapy,
prior fluoroquinolone use for more than 5 days before randomization, positive culture for S.
aureus only from a central intravenous catheter, neutropenia (<0.5 x 109 L-1), failure to supply
informed consent, meningitis or imprisonment. Each patient was recruited into the study only
once to avoid double inclusion in cases with repeated bacteremia. The protocol was approved
by the ethics committees of all study sites. Written informed consent was obtained from all
patients or their representatives. All patients were treated with an antimicrobial agent effective
against the S. aureus strain isolated in vitro beginning on the day of the positive blood culture.
Definitions
Intravenous drug users (IDUs) were defined as patients who had injected drugs within the past
6 months prior to randomization based on a history taken upon admission. SAB was hospital-
acquired if the first positive blood culture was obtained48 hours after admission or the
patient was a resident in a long-term care facility or had attended hemodialysis within the pre-
ceding 2 months. The prognosis and severity of underlying diseases were characterized as
healthy, nonfatal, ultimately or rapidly fatal disease according to the criteria of McCabe and
Jackson [22]. The infection foci were documented based on clinical, bacteriological, radiologi-
cal, or pathological investigations. Endocarditis was defined by modified Duke criteria [23].
Deep infection foci included, endocarditis, pneumonia, deep-seated abscess, osteomyelitis, sep-
tic arthritis, mediastinitis, and any foreign-body infection. Definitive deep infection foci were
verified by bacteriological, radiological or pathological investigations but they were regarded as
suspected if it was evident from clinical findings only. Definition of severe sepsis was sepsis in
combination with hypotension, hypoperfusion or organ failure [24]. Mortality was recorded at
30 days.
Analytical methods
Blood samples for CRP measurement and white blood cell counts (WBC counts) were rou-
tinely collected on the day of the positive blood culture for S. aureus from all patients. Thereaf-
ter, samples were collected every other day during the first week, twice a week during
hospitalization and at 28 days. Serum concentrations of CRP and WBC counts were measured
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in the study site laboratory using standard laboratory methods. The serum or plasma was sub-
jected to automatic immunoturbidimetric analysis using the 917 or Modular PP-analyzer
(Hitachi Ltd, Tokyo, Japan) and Tina-quant CRP reagents (Roche Diagnostics, Tina-quant
CRP). The normal value of the CRP concentration was<10 mg/L for both methods.
Statistical analysis
First, a test for normality was performed and parametric tests were chosen when possible. The
associations between categorical variables were analyzed by Pearson’s χ2-test or Fisher’s exact
test as appropriate. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined to
estimate the significance of differences between the groups. All tests were two-tailed and
p<0.05 was considered significant. Hazard ratios (HR) of CRP and WBC count cut-off values
for 30-day mortality were calculated by the Cox regression analysis adjusted with the prognos-
tic factors. Adjusted Odds ratios (OR) for factors associated with deep infection foci were ana-
lyzed by binary logistic regression analysis. In both multivariable analyses, forward selection
was performed using the Akaike information criteria (AIC) [25] which includes significant
covariates with p<0.20. Receiver operating characteristic (ROC) analysis was used to evaluate
the prognostic value of CRP and WBC in predicting 30-day mortality and the presence of deep
infections. Abnormal leukocytes were analyzed by the χ2-test. The area under the curve (AUC)
was calculated for each ROC. The cut-off points for general optimal tests were chosen to opti-
mize the rate of true positives whilst minimizing the rate of false positives. SPSS1 version 20.0
(SPSS Inc., Chicago, IL, USA) was used for data analysis.
Results
Clinical outcome and deep infections
Fifty-three cases (12%) out of 430 patients with SAB had a fatal outcome within 30 days after
the positive blood culture. Table 1 shows the results of both univariate and multivariate analy-
sis for characteristics, predisposing factors and severity of illness stratified according to 30-day
mortality. Age>60 years, chronic alcoholism, fatal underlying disease, chronic renal failure,
severe sepsis during the first 3 days, pneumonia or endocarditis were found as significant prog-
nostic factors in multivariate analysis. Deep infection focus was diagnosed already at day 3
after the positive blood culture in 325 (75%) patients. Within 30-day follow-up a deep focus
was found in total in 351 patients (82%), including a deep seated abscess in 185 (43%) patients,
osteomyelitis in 141 (33%) patients, pneumonia in 152 (35%) patients, infection of a foreign
body in 79 (18%) patients, endocarditis in 74 (17%) patients, and septic arthritis in 56 (13%)
patients.
Predictors of a fatal outcome
The CRP concentration was in an average highest on the day of the positive blood culture and
declined gradually thereafter as shown in Fig 1A. In cases with fatal outcome, the mean CRP
level differed from the survivors by day 4, and the difference remained significant throughout
the observation period as shown in Fig 1B. The median CRP level in fatal cases at day 4 was
127 mg/L (interquartile range [IQR], defined as the difference between the third and the first
quartile, 97 mg/L), which was higher than the median value in the survivors (91 mg/L, IQR, 96
mg/L, p = 0.005).
The CRP levels at day 4, 7, and 14 after the positive blood culture were found to be signifi-
cantly associated with 30-day mortality based on the ROC analysis whereas WBC counts were
significant in regard to mortality only at days 7 and 14 as shown in Fig 2. Optimal cut-off value
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of CRP at day 4 was: 104 mg/L with sensitivity of 77% and specificity of 55%, at day 7day CRP
66 mg/L with sensitivity of 73% and specificity of 55% and at 14 day CRP 61mg/L with sensitiv-
ity of 82% and specificity of 80%. For WBC count optimal cut-off value for was 9.8 x109/L at
day 7 with sensitivity of 77% and specificity of 62% and 8.6 x109/L at day 14 with sensitivity of
77% and specificity of 78%. At the time of the positive blood culture, the CRP levels and WBC
counts could not significantly predict patients with fatal outcome.
Univariate analysis calculated for CRP and WBC optimal cut-off values gave odds ratios for
30-day mortality as shown in Table 2. All CRP cut-off levels were found as significant predic-
tors for mortality in univariate analysis. In univariate analysis. WBC count cut-off at day 7 of
9.8 x109/L had an OR of 3.6 (95% CI, 1.8–7.0; p<0.0001) when also lowWBC count levels
were taken into account by using a combined parameter with a WBC<4.5 or>9.8 x109/L.
Prognostic factors, comprising characteristics, predisposing factors and severity of illness, from
Table 1, were analysed in multivariate analysis together with the cut-off values of CRP and
WBC at days 4, 7 and 14 and the results are shown in Table 2. The cut-off values for CRP at
day 4>103 mg/L, at day 14> 61 mg/L and fall of CRP concentration less than by 50% in
Table 1. Characteristics, predisposing factors and severity of illness in 430 patients with Staphylococcus aureus bacteremia (SAB) stratified
according to 30-daymortality. OR = odds ratio for fatal outcome. HR = hazard ratio for fatal outcome, 95% CI = 95% confidence interval. All values are
given as number of patients (%).
Univariate analysis Multivariate analysisf
Fatalitiesn = 53 (12) Survivors n = 377 (88) OR (95% CI) p- value HR (95% CI) p-value
Age >60 years 43 (80) 174 (46) 5.0 (2.4–10.3) <0.0001 4.2 (2.0–8.6) <0.0001
Male sex 33 (62) 235 (62) 1.0 (0.6–1.8) 1.000 - -
Healthcare-associated SAB 32 (60) 200 (53) 1.3 (0.8–2.4) 0.378 - -
Foreign bodyb 12 (23) 100 (27) 0.8 (0.4–1.6) 0.619 - -
Intravenous drug abusea 1 (2) 43 (11) 0.15 (0.0–1.1) 0.029 - -
Immunosuppressive treatment 16 (30) 42 (11) 3.5 (1.8–6.7) <0.0001 1.8 (0.9–3.3) 0.087
Chronic alcoholism 11 (21) 37 (10) 2.4 (1.1–5.1) 0.032 2.7 (1.2–6.1) 0.017
Diabetes 13 (25) 95 (25) 1.0 (0.5–1.9) 1.000 0.5 (0.3–1.19 0.090
Chronic renal failurec 14 (26) 46 (12) 2.6 (1.3–5.1) 0.010 2.3 (1.1–5.1) 0.037
Liver disease 7 (13) 60(16) 0.8 (0.3–1.9) 0.691 - -
Malignancy 13 (25) 50 (13) 2.1 (1.0–4.3) 0.038 - -
HIV 1 (2) 7 (2) 1.0 (0.1–8.2) 1.000 - -
Ultimately or rapidly fatal diseased 31 (59) 88 (23) 4.6 (2.5–8.4) <0.0001 2.1 (1.1–4.0) 0.033
Severe sepsise 12 (23) 25 (7) 4.1 (1.9–8.8) 0.001 2.1 (1.0–4.3) 0.054
Any deep infection 51 (96) 300 (80) 6.5 (1.6–27.5) 0.002 4.1 (0.9–18.4) 0.065
Deep seated abscess 23 (43) 162 (43) 1.0 (0.6–1.8) 1.000 - -
Osteomyelitis 17 (32) 124 (33) 1.0 (0.5–1.6) 1.000 - -
Pneumonia 34 (64) 118 (31) 3.9 (2.2–7.2) <0.0001 2.0 (1.1–3.7) 0.033
Foreign body infection 9 (17) 70 (19) 0.9 (0.4–1.9) 1.000 - -
Endocarditis 17 (32) 57 (15) 2.6 (1.4–4.9) 0.006 2.5 (1.4–4.7) 0.004
Septic arthritis 4 (8) 52 (14) 0.5 (0.2–1.5) 0.276 - -
aInjection drug use within 6 months.
bForeign body implanted within a year.
cConstantly elevated serum creatinine (180 μmol/l).
dAccording to the criteria of McCabe and Jackson [22].
eSevere sepsis during the 3 days from the blood culture time point.
f Cox regression analysis -2 log likelihood was 547.718 and model chi-square 100.102, p<0.0001
doi:10.1371/journal.pone.0155644.t001
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Fig 1. C-reactive protein (CRP) (Mean ±SEM) levels in patients with Staphylococcus aureus
bacteremia (SAB) within 30 days of the positive blood culture. (A) All 430 SAB patients. (B) SAB patients
with a fatal outcome within 30 days (n = 53) and survivors (n = 377). (C) Mean CRP levels stratified according
to the presence (n = 351) or absence (n = 79) of deep infection focus. Stars indicate p-values of the Student’s
T-test. * p<0.05, ** p<0.01 and *** p<0.001.
doi:10.1371/journal.pone.0155644.g001
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Fig 2. Receiver-operating characteristic (ROC) curve analyses of C-reactive protein (CRP)
concentrations and white blood cell counts (WBC) with respect to 30-daymortality in Staphylococcus
aureus bacteremia (n = 430). The area under the curve (AUC) for CRP on the day 4 was 0.65 (95%CI,
0.55–0.76; p = 0.016) with a cut-off value of 104 mg/L with sensitivity of 77% and specificity of 55%. For CRP
on the day 7 the AUC was 0.68 (95%CI, 0.58–0.79; p = 0.004) with a cut-off value of 66 mg/L with sensitivity
of 73% and specificity of 55% and for CRP on day 14 the AUC was 0.86 (95%CI, 0.79–0.94; p<0.0001) with
a cut-off value of 61mg/L with sensitivity of 82% and specificity of 80%. The corresponding AUC for WBC on
the day 4 was 0.60 (95%CI, 0.49–0.71; p = 0.116) with a cut-off value of 8.0 x109/L with sensitivity of 86%
and specificity of 41%. For WBC on the day 7 the AUC was 0.70 (95%CI, 0.62–0.78; p = 0.002) with a cut-off
value of 9.8 x109/L with sensitivity of 77% and specificity of 62%. For WBC on the day 14 the AUC was 0.80
(95%CI, 0.70–0.92; p<0.0001) with a cut-off value of 8.6 x109/L with sensitivity of 77% and specificity of 78%.
doi:10.1371/journal.pone.0155644.g002
Table 2. Cut-off values for C-reactive protein (CRP) levels (mg/L) and white blood cell counts (WBC) in finding patients with fatal outcome among
430 patients with Staphylococcus aureus bacteremia. OR = odds ratio for fatal outcome. HR = hazard ratio for fatal outcome, 95%CI = 95% confidence
interval. All values are given as number of patients (%).
Univariate analysis Multivariate analysisa
Cut-off value Fatalities n = 53 (12) Survivors n = 377 (88) OR 95% (CI) p-value HR (95%CI) p-value
CRP >103 mg/L at day 4 33 (66) 158 (43) 2.6 (1.4–4.8) 0.004 3.5 (1.2–10.3) 0.024
CRP >66 mg/L at day 7 27 (66) 155 (43) 2.6 (1.3–5.1) 0.005 - -
CRP >61 mg/L at day 14 21 (84) 74 (21) 19.8 (6.6–59.4) <0.0001 3.6 (1.1–10.3) 0.039
Fall of CRP <50% in 14 days 13 (52) 56 (16) 5.7 (2.5–13.1) <0.0001 2.0 (0.8–5.4) 0.148
Fall of CRP <50% between 7 to 14 days 20 (87) 151 (44) 8.5 (2.5–29.2) <0.0001 - -
WBC <4.5 or >10.3 x109/L at day 4 32 (63) 166 (45) 2.0 (1.1–3.7) 0.024 - -
WBC <4.5 or >9.8 x109/L at day 7 34 (81) 153 (42) 5.8 (2.6–12.8) <0.0001 - -
WBC >8.6 x109/L at day 14 17 (65) 80 (23) 6.5 (2.8–15.0) <0.0001 8.2 (2.9–23.1) <0.0001
Age >60 years 43 (80) 174 (46) 5.0 (2.4–10.3) <0.0001 3.6 (1.1–11.5) 0.029
Malignancy 13 (25) 50 (13) 2.1 (1.0–4.3) 0.038 0.3 (0.1–1.2) 0.087
Ultimately or rapidly fatal diseaseb 31 (59) 88 (23) 4.6 (2.5–8.4) <0.0001 6.5 (2.4–17.6) <0.0001
Pneumonia 34 (64) 118 (31) 3.9 (2.2–7.2) <0.0001 8.1 (2.5–25.8) <0.0001
aCox regression analysis -2 log likelihood was 169.320 and chi-square 92.437, p<0.0001. All factors from Table 1 were included in the analysis.
bAccording to the criteria of McCabe and Jackson [22].
doi:10.1371/journal.pone.0155644.t002
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14 days were all markers of poor prognosis also in multivariate analysis. Overall -2 log likeli-
hood of the predictive power of the multivariable model including the CRP andWBC count
cut-off values (Table 2) was (-2 log likelihood 547.718, chi-square 100.102, p<0.0001) and it
was superior as compared to the model (Table 1) without them (-2 log likelihood 547.718, chi-
square 100.102, p<0.0001)
Predictors of deep infection foci
The CRP levels in patients with a deep infection focus compared to those without a deep infec-
tion was significantly higher on the day of the positive blood culture and throughout the
30-day period as shown in Fig 1C.
The CRP levels on the day of the positive blood culture and at days 7 and 14 after that were
significantly associated with the presence of any deep infection during the 30-day surveillance
period whereas WBC counts were significant only at day 7. ROC curve analysis results are
shown in Fig 3. The optimal CRP cut-off value for screening a deep infection focus was 108
mg/L at day 1 with sensitivity of 77% and specificity of 60%, 44 mg/L at day 7 with sensitivity
of 68% and specificity of 67%, and 22 mg/L at day 14 with sensitivity of 59% and specificity of
76%. The optimal WBC count cut-off value at day 7 was 8.5 x109/L with sensitivity of 59% and
specificity of 62%. On the day of the positive blood culture and at day 14 WBC count were not
significant.
Table 3 shows all clinical factors associated by univariate analysis with the presence of deep
infection. Multivariate analysis of all these clinical factors and CRP andWBC cut-off values
indicates that an intravenous drug abuse was the strongest predictor for the presence of any
deep infection focus with OR 11.9 (95% CI, 1.5–93.2; p = 0.018) and CRP>108 mg/L at day 1
Fig 3. Receiver-operating characteristic (ROC) curve analyses of C-reactive protein (CRP)
concentrations and white blood cell counts (WBC) with respect to presence of any deep infection
focus recorded during 30-days. The area under the curve (AUC) for the day of the positive blood culture,
CRP was 0.074 (95%CI, 0.67–0.81; p<0.0001) with a cut-off value of 108 mg/L with sensitivity of 77% and
specificity of 60%. For CRP on day 7, the AUC was 0.75 (95% CI, 0.68–0.81; p<0.0001) with a cut-off value of
44 mg/L with sensitivity of 68% and specificity of 67% and for CRP on day 14 the AUC was 0.70 (95% CI,
0.64–0.77; p<0.0001) with a cut-off value of 22 mg/L with sensitivity of 59% and specificity of 68%. The
corresponding AUC for WBC on the day 1 was 0.55 (95%CI, 0.46–0.63; p = 0.236) and a cut-off value was
not determined. For WBC on day 7 the AUC was 0.65 (95%CI, 0.58–0.72; p<0.0001) with a cut-off value of
8.5 x109/L with sensitivity of 59% and specificity of 62%. For WBC on 14 days, the AUC was 0.56 (95% CI,
0.49–0.63; p = 0.153) with a cut-off value of 7.25 x109/L with sensitivity of 44% and specificity of 75%.
doi:10.1371/journal.pone.0155644.g003
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with OR 2.6 (95% CI, 1.3–4.9; p = 0.005) and CRP>22 mg/L at day 14 with OR 3.9 (95% CI,
1.6–9.5; p = 0.003) were the second strongest. CRP at day 7>44 mg/L and change of
CRP<50% within 14 days or during the second week and all WBC count cut-off values were
non-significant.
Discussion
CRP and WBC counts are usually followed during the treatment of serious infections such as
SAB. Constantly elevated values are usually regarded as alarming signals, but clear cut-off
points to aid in clinical decisions have not been identified. Validated tests with clearly defined
limits might save costs if they could help to guide treatment efforts and examinations to the
right patients and simplify the treatment of patients with a low risk for fatal outcomes or
complications.
We observed that the decline of CRP deviated in patients with fatal outcome compared to
the survivors already on the 4th day after the positive blood culture. In addition, abnormal
WBC counts and CRP at the end of the second week significantly predicted a risk of fatal out-
come within 30 days. The CRP levels and WBC counts were both significant predictors of fatal
outcome when adjusted for the identified risk factors for fatal outcome in the multivariate anal-
ysis. Furthermore, the CRP level was higher among patients with a deep infection focus already
Table 3. Factors associated with a deep infection focus in 430 patients with Staphylococcus aureus bacteremia. OR = odds ratio for presence of
deep infection, 95%CI = 95% confidence interval. All values are given as number of patients (%).
Univariate analysis Multivariate analysisa
Deep infection n = 351
(82)
No deep infection n = 79
(18)
OR (95% CI) p-value OR (95%CI) p-value
Male sex 224 (84) 44 (56) 1.4 (0.86–2.3) 0.199 - -
Hospital-acquired 178 (51) 54 (68) 0.48 (0.3–
0.80)
0.006 - -
Foreign bodyb 82 (23) 30 (38) 0.50 (0.3–0.8) 0.010 - -
IDUc 43 (12) 1 (1) 11 (1.5–80.3) 0.002 11.9 (1.5–
93.2)
0.018
Chronic renal failured 42 (12) 18 (23) 0.5 (0.2–0.9) 0.064 0.47 (0.2–1.0) 0.064
Malignancy 49 (78) 14 (22) 0.8 (0.4–1.4) 0.383 - -
CRP >108 mg/L at day 1 264 (76) 31 (39) 4.9 (2.9–8.2) <0.0001 2.6 (1.3–4.9) 0.005
CRP >72 mg/L at day 4 229 (68) 30 (39) 3.4 (2.0–5.6) <0.0001 - -
CRP >44 mg/L at day 7 223 (67) 20 (27) 5.7 (3.2–10) <0.0001 2.0 (1.0–4.3) 0.063
CRP >22 mg/L at day 14 177 (57) 16 (23) 4.4 (2.4–8.1) <0.0001 3.9 (1.6–9.5) 0.003
Fall of CRP <50% in 14 days 53 (17) 16 (23) 0.7 (0.4–1.3) 0.301 - -
Fall of CRP <50% during the second
week
136 (46) 35 (52) 0.8 (0.5–1.3) 0.420 0.5 (0.2–1.0) 0.064
WBC >8.0 x109/L at day 4 215 (63) 34 (44) 2.2 (1.4–3.7) 0.002 - -
WBC >8.5 x109/L at day 7 189 (57) 27 (37) 2.4 (1.4–4.0) 0.001 - -
WBC >7.25 x109/L at day 14 139 (45) 19 (28) 2.1 (1.2–3.8) 0.010 - -
Deep infection occurred at any time within the 30-day follow-up.
aBinary logistic regression analysis results
bForeign body implanted within a year
cIntravenous drug abuse during the 6 months preceding the positive blood culture.
dChronically elevated serum creatinine (180 μmol/l).
doi:10.1371/journal.pone.0155644.t003
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on the day of the positive blood culture and at 2 weeks compared to patients in whom a deep
infection focus was not verified.
Both CRP and WBC seemed to predict the risk for fatal outcome fairly well. The ROC-curve
analysis suggested that CRP might be a slightly better prognostic marker due to its higher AUC
value, but the cut-off values for CRP (over 66 mg/L) and WBC (over 9.8 x 109/L) at one week
had fairly similar sensitivities (0.73–0.77) and specificities (0.55–0.62), suggesting approxi-
mately equal clinical accuracy. However, when all other risk factors for fatal outcome were
taken into account only CRP at day 4 (over 103 mg/L) and at the end of the second week both
CRP (over 61 mg/L) andWBC (over 8.6x109/L) remained significant.
In accordance with our results, CRP levels were observed to correlate with fatal outcome in
sepsis [26] and in severe community acquired pneumonia [27–29]. However, contrasting
results have also been published for bacteremia patients with no association of CRP levels with
fatal outcome [30]. CRP was not observed to predict hospital mortality in sepsis patients [31],
and CRP levels on the day of sepsis diagnosis poorly predicted survival [32]. In contrast to our
findings, these studies included various causes of systemic inflammatory response (SIRS) and
included both patients with an infection and non-infectious causes whereas we included only
bacteremic patients with sepsis and further focused on only one causative agent. This difference
in results suggests that the particular cut-off points for fatal outcome might be determined spe-
cifically for each disease.
Mortality in SAB is high but variable in recent studies [9,33–35]. In our study, the mortality
at 30 days was 12%, which was at the lower end of the mortality range reported in recent publi-
cations [33,35]. All our patients received effective antimicrobial therapy from the day of the
positive blood culture, and we did not include any cases due to MRSA. We may have missed
some of the most serious cases due to problems in enrolling them into the study but patients
treated both in the general ward and in intensive care unit were recruited. The treatment of
septic patients has certainly changed since this patient material was collected but the mortality
in SAB is virtually unchanged. The low mortality in our patient material suggests that the
results might be extrapolated even into current treatment practice. The low mortality in our
study may have decreased the power to detect the predictive value of CRP levels and WBC
counts for fatal outcome and may also have affected the extrapolation of cut-off values to other
patient groups.
The prognosis of SAB is significantly affected by the severity of the underlying diseases [8]
and the presence of deep infection foci or complications such as endocarditis, osteomyelitis or
foreign body infections [3,36]. Intravenous antibiotic treatment is recommended for 4–6 weeks
in SAB patients with a deep infection focus, and the relatively high recurrence of SAB (9–23%)
could be partially explained by unidentified deep infections [4,37–40]. A meticulous search for
deep infections may improve the prognosis and is best achieved by an infectious disease spe-
cialist consultation [9,35,41,42]. Therefore, inexpensive markers to detect the presence of deep
infections might be useful to guide diagnostic procedures or limit support that might be not
needed.
CRP seemed to be of greater value thanWBC in predicting the presence of a deep infection
focus. CRP levels higher than 108 mg/L on the day of the positive blood culture significantly
suggested the presence of a deep infection focus with an acceptable sensitivity of 0.77. CRP lev-
els greater than 44 mg/L at one week and 22 mg/L at two weeks were also significant prognostic
markers for a deep infection focus with a somewhat higher specificity compared to the CRP
level on the day of the positive blood culture. Moreover, an elevated WBC count detected
patients with a deep infection focus in univariate analysis but these differences were not signifi-
cant in the multivariate analysis.
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Few other biomarkers have been evaluated for the detection of deep infection focus. In our
earlier publication, the soluble urokinase receptor (suPAR) was prognostic for fatal outcome in
SAB patients but it was not helpful in finding deep infections [11]. The erythrocyte sedimenta-
tion rate (ESR) was sensitive but nonspecific for the detection of osteomyelitis [43,44]. Procal-
citonin (PCT) was shown to be sensitive and useful for the differential diagnosis of infectious
or non-infectious inflammatory processes in various conditions [45]. However, the use of PCT
to detect deep infections in SAB patients has not been studied. Cell-free DNA in plasma was
observed to be a good prognostic marker of fatal outcome among SAB patients treated in inten-
sive care units but did not predict the presence of a deep infection focus [13].
We previously reported that the maximal CRP in SAB was affected by genetic polymor-
phisms in the genes regulating CRP synthesis [19]. In accordance, the CRP on the day of the
positive blood culture was not a significant prognostic marker for fatal outcome. Because the
CRP level might be individually set, we also analyzed the prognostic value of the relative decline
in the CRP level during the first two weeks. The lack of a 50% decrease in the CRP level in the
first two weeks (OR 8.2) or during the second week (OR 9.5) were both predictors of a fatal out-
come in univariate analysis, but not in multivariate analysis. This finding suggests that clini-
cians should not only look for the absolute cut-off values but also follow the decline of CRP
when assessing the risk for a fatal outcome in individual patients. Interestingly, the lack of
decline of CRP was not observed to be a predictor of a deep infection focus. This finding sug-
gests that the presence of a deep infection could lead to a higher level of inflammation as mea-
sured by higher CRP levels, but the CRP level would also decline concomitantly in cases with a
deep infection focus.
In conclusion, we evaluated the prognostic impact of two widely followed inexpensive labo-
ratory markers for SAB, which is one of the most common bacteremias. CRP levels higher than
103 mg/L at day 4 and higher than 61 mg/L at day 14 were significant markers for a fatal out-
come like WBC over 8.6 x 109/L or lower than 4.5 x 109/ at day 14. The presence of a deep
infection was predicted by a CRP level greater than 108 mg/L already on the day of the positive
blood culture and by CRP greater than 22 mg/L at two weeks. These cut-off values might be
helpful in guiding clinicians treating patients with SAB
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